167 related articles for article (PubMed ID: 19148184)
1. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis.
Michalak EM; Jansen ES; Happo L; Cragg MS; Tai L; Smyth GK; Strasser A; Adams JM; Scott CL
Cell Death Differ; 2009 May; 16(5):684-96. PubMed ID: 19148184
[TBL] [Abstract][Full Text] [Related]
2. P53 and BCL-2 family proteins PUMA and NOXA define competitive fitness in pluripotent cell competition.
Valverde-Lopez JA; Li-Bao L; Sierra R; Santos E; Giovinazzo G; Díaz-Díaz C; Torres M
PLoS Genet; 2024 Mar; 20(3):e1011193. PubMed ID: 38489392
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis.
Tuzlak S; Haschka MD; Mokina AM; Rülicke T; Cory S; Labi V; Villunger A
FEBS J; 2018 Apr; 285(8):1403-1418. PubMed ID: 29498802
[TBL] [Abstract][Full Text] [Related]
4. Caspase-resistant ROCK1 expression prolongs survival of Eµ-Myc B cell lymphoma mice.
Mardilovich K; Naylor G; Julian L; Phinichkusolchit N; Keeshan K; Blyth K; Olson MF
Dis Model Mech; 2024 May; 17(5):. PubMed ID: 38616733
[TBL] [Abstract][Full Text] [Related]
5. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.
Happo L; Cragg MS; Phipson B; Haga JM; Jansen ES; Herold MJ; Dewson G; Michalak EM; Vandenberg CJ; Smyth GK; Strasser A; Cory S; Scott CL
Blood; 2010 Dec; 116(24):5256-67. PubMed ID: 20829369
[TBL] [Abstract][Full Text] [Related]
6. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E; Sandoz J; Romero G; Zadra I; Urgel-Solas J; Borredat P; Kourtis S; Ortet L; Martínez CM; Weghorn D; Sdelci S; Janic A
J Exp Clin Cancer Res; 2024 Apr; 43(1):127. PubMed ID: 38685100
[TBL] [Abstract][Full Text] [Related]
7. Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice.
Brennan MS; Brinkmann K; Romero Sola G; Healey G; Gibson L; Gangoda L; Potts MA; Lieschke E; Wilcox S; Strasser A; Herold MJ; Janic A
Cell Death Differ; 2024 Feb; 31(2):159-169. PubMed ID: 38110554
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag directly activates BAK and induces apoptosis.
Chen M; Hu L; Bao X; Ye K; Li Y; Zhang Z; Kaufmann SH; Xiao J; Dai H
Cell Death Dis; 2023 Jul; 14(7):394. PubMed ID: 37393297
[TBL] [Abstract][Full Text] [Related]
9. Apoptotic cell death in disease-Current understanding of the NCCD 2023.
Vitale I; Pietrocola F; Guilbaud E; Aaronson SA; Abrams JM; Adam D; Agostini M; Agostinis P; Alnemri ES; Altucci L; Amelio I; Andrews DW; Aqeilan RI; Arama E; Baehrecke EH; Balachandran S; Bano D; Barlev NA; Bartek J; Bazan NG; Becker C; Bernassola F; Bertrand MJM; Bianchi ME; Blagosklonny MV; Blander JM; Blandino G; Blomgren K; Borner C; Bortner CD; Bove P; Boya P; Brenner C; Broz P; Brunner T; Damgaard RB; Calin GA; Campanella M; Candi E; Carbone M; Carmona-Gutierrez D; Cecconi F; Chan FK; Chen GQ; Chen Q; Chen YH; Cheng EH; Chipuk JE; Cidlowski JA; Ciechanover A; Ciliberto G; Conrad M; Cubillos-Ruiz JR; Czabotar PE; D'Angiolella V; Daugaard M; Dawson TM; Dawson VL; De Maria R; De Strooper B; Debatin KM; Deberardinis RJ; Degterev A; Del Sal G; Deshmukh M; Di Virgilio F; Diederich M; Dixon SJ; Dynlacht BD; El-Deiry WS; Elrod JW; Engeland K; Fimia GM; Galassi C; Ganini C; Garcia-Saez AJ; Garg AD; Garrido C; Gavathiotis E; Gerlic M; Ghosh S; Green DR; Greene LA; Gronemeyer H; Häcker G; Hajnóczky G; Hardwick JM; Haupt Y; He S; Heery DM; Hengartner MO; Hetz C; Hildeman DA; Ichijo H; Inoue S; Jäättelä M; Janic A; Joseph B; Jost PJ; Kanneganti TD; Karin M; Kashkar H; Kaufmann T; Kelly GL; Kepp O; Kimchi A; Kitsis RN; Klionsky DJ; Kluck R; Krysko DV; Kulms D; Kumar S; Lavandero S; Lavrik IN; Lemasters JJ; Liccardi G; Linkermann A; Lipton SA; Lockshin RA; López-Otín C; Luedde T; MacFarlane M; Madeo F; Malorni W; Manic G; Mantovani R; Marchi S; Marine JC; Martin SJ; Martinou JC; Mastroberardino PG; Medema JP; Mehlen P; Meier P; Melino G; Melino S; Miao EA; Moll UM; Muñoz-Pinedo C; Murphy DJ; Niklison-Chirou MV; Novelli F; Núñez G; Oberst A; Ofengeim D; Opferman JT; Oren M; Pagano M; Panaretakis T; Pasparakis M; Penninger JM; Pentimalli F; Pereira DM; Pervaiz S; Peter ME; Pinton P; Porta G; Prehn JHM; Puthalakath H; Rabinovich GA; Rajalingam K; Ravichandran KS; Rehm M; Ricci JE; Rizzuto R; Robinson N; Rodrigues CMP; Rotblat B; Rothlin CV; Rubinsztein DC; Rudel T; Rufini A; Ryan KM; Sarosiek KA; Sawa A; Sayan E; Schroder K; Scorrano L; Sesti F; Shao F; Shi Y; Sica GS; Silke J; Simon HU; Sistigu A; Stephanou A; Stockwell BR; Strapazzon F; Strasser A; Sun L; Sun E; Sun Q; Szabadkai G; Tait SWG; Tang D; Tavernarakis N; Troy CM; Turk B; Urbano N; Vandenabeele P; Vanden Berghe T; Vander Heiden MG; Vanderluit JL; Verkhratsky A; Villunger A; von Karstedt S; Voss AK; Vousden KH; Vucic D; Vuri D; Wagner EF; Walczak H; Wallach D; Wang R; Wang Y; Weber A; Wood W; Yamazaki T; Yang HT; Zakeri Z; Zawacka-Pankau JE; Zhang L; Zhang H; Zhivotovsky B; Zhou W; Piacentini M; Kroemer G; Galluzzi L
Cell Death Differ; 2023 May; 30(5):1097-1154. PubMed ID: 37100955
[TBL] [Abstract][Full Text] [Related]
10. Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma.
Winkler R; Piskor EM; Kosan C
Cells; 2022 Dec; 12(1):. PubMed ID: 36611833
[TBL] [Abstract][Full Text] [Related]
11. BCL-2 protein family: attractive targets for cancer therapy.
Kaloni D; Diepstraten ST; Strasser A; Kelly GL
Apoptosis; 2023 Feb; 28(1-2):20-38. PubMed ID: 36342579
[TBL] [Abstract][Full Text] [Related]
12. Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition.
Winkler R; Mägdefrau AS; Piskor EM; Kleemann M; Beyer M; Linke K; Hansen L; Schaffer AM; Hoffmann ME; Poepsel S; Heyd F; Beli P; Möröy T; Mahboobi S; Krämer OH; Kosan C
Oncogene; 2022 Sep; 41(40):4560-4572. PubMed ID: 36068335
[TBL] [Abstract][Full Text] [Related]
13. Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.
Deng Y; Diepstraten ST; Potts MA; Giner G; Trezise S; Ng AP; Healey G; Kane SR; Cooray A; Behrens K; Heidersbach A; Kueh AJ; Pal M; Wilcox S; Tai L; Alexander WS; Visvader JE; Nutt SL; Strasser A; Haley B; Zhao Q; Kelly GL; Herold MJ
Nat Commun; 2022 Aug; 13(1):4739. PubMed ID: 35961968
[TBL] [Abstract][Full Text] [Related]
14. Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?
Thomas AF; Kelly GL; Strasser A
Cell Death Differ; 2022 May; 29(5):961-971. PubMed ID: 35396345
[TBL] [Abstract][Full Text] [Related]
15. Should mutant TP53 be targeted for cancer therapy?
Wang Z; Strasser A; Kelly GL
Cell Death Differ; 2022 May; 29(5):911-920. PubMed ID: 35332311
[TBL] [Abstract][Full Text] [Related]
16. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.
Diepstraten ST; Anderson MA; Czabotar PE; Lessene G; Strasser A; Kelly GL
Nat Rev Cancer; 2022 Jan; 22(1):45-64. PubMed ID: 34663943
[TBL] [Abstract][Full Text] [Related]
17. At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity.
Rizzotto D; Englmaier L; Villunger A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639222
[TBL] [Abstract][Full Text] [Related]
18. IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3.
Petrenko O; Li J; Cimica V; Mena-Taboada P; Shin HY; D'Amico S; Reich NC
PLoS One; 2021; 16(3):e0247394. PubMed ID: 33651821
[TBL] [Abstract][Full Text] [Related]
19. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
Domostegui A; Peddigari S; Mercer CA; Iannizzotto F; Rodriguez ML; Garcia-Cajide M; Amador V; Diepstraten ST; Kelly GL; Salazar R; Kozma SC; Kusnadi EP; Kang J; Gentilella A; Pearson RB; Thomas G; Pelletier J
Blood; 2021 Jun; 137(24):3351-3364. PubMed ID: 33512431
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
